A Single Center, Open Label, Phase 1 Study in Healthy Participants to Investigate the Drug-Drug Interactions Between TNP-2198 and Midazolam, Clarithromycin

This is a single center, open label, drug-drug interaction, Phase 1 study of TNP-2198 in approximately 32 healthy participants, includes 2 cohorts (16 participants per cohort): Midazolam cohort and Clarithromycin cohort. Midazolam cohort will evaluate the effect of multiple oral doses of TNP-2198 capsules on the pharmacokinetics (PK) parameters of a single oral dose of midazolam, a cytochrome P-450 (CYP) 3A sensitive substrate, in healthy participants; Clarithromycin cohort will evaluate the effect of multiple oral doses of clarithromycin tablets, a strong CYP3A and P-gp inhibitor, on the PK parameters of multiple oral doses of TNP-2198 in healthy participants.

开始日期2024-08-26

申办/合作机构

丹诺医药（苏州）有限公司

CTR20242839 / Completed临床1期

在健康受试者中评价TNP-2198与咪达唑仑、克拉霉素药物相互作用的单中心、开放、I 期临床研究

主要目的——咪达唑仑组：在健康受试者中评价TNP-2198 胶囊多次口服给药对咪达唑仑口服溶液单次口服给药药代动力学（PK）参数的影响；克拉霉素组：在健康受试者中评价克拉霉素片多次口服给药对TNP-2198 胶囊多次口服给药PK 参数的影响。次要目的——咪达唑仑组：在健康受试者中评价咪达唑仑口服溶液单次口服给药或与TNP-2198 胶囊多次同时口服给药的安全耐受性；克拉霉素组：在健康受试者中评价TNP-2198 胶囊多次口服给药或与克拉霉素片多次同时口服给药的安全耐受性。

开始日期2024-08-22

申办/合作机构

丹诺医药（苏州）有限公司

NCT05857163 / Completed临床3期

Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of Rifasutenizol (TNP 2198) in Combination With Rabeprazole and Amoxicillin in the Primary Treatment of Participants With H. Pylori Infection

A multi-center, randomized, double-blind, bismuth-containing quadruple active comparator-controlled Phase 3 clinical study to evaluate the efficacy and safety of Rifasutenizol in combination with rabeprazole and amoxicillin in the primary treatment of participants with H. pylori infection using an adaptive design with sample size re-estimation.
Subjects will be randomly assigned to test group or control group at a 1:1 ratio stratified by study site, and will receive Rifasutenizol capsules, rabeprazole sodium enteric-coated tablets, amoxicillin capsules combined with clarithromycin placebo tablets and bismuth potassium citrate placebo capsules (test group), or bismuth-containing quadruple regimen of amoxicillin capsules, clarithromycin tablets, rabeprazole sodium enteric-coated tablets and bismuth potassium citrate capsules combined with RSZ placebo capsules (control group) for 14 consecutive days.
13C UBT will be performed 4 6 weeks after the last dose to evaluate the eradication effect of H. pylori.

开始日期2023-05-18

申办/合作机构

丹诺医药（苏州）有限公司

100 项与瑞法舒坦唑相关的临床结果

登录后查看更多信息

100 项与瑞法舒坦唑相关的转化医学

登录后查看更多信息

100 项与瑞法舒坦唑相关的专利（医药）

登录后查看更多信息

项与瑞法舒坦唑相关的文献（医药）

2024-06-01·The Lancet Infectious Diseases

Safety, pharmacokinetics, and efficacy of rifasutenizol, a novel dual-targeted antibacterial agent in healthy participants and patients in China with Helicobacter pylori infection: four randomised clinical trials

Article

作者: Lou, Jinfeng ; Wang, Jing ; Ma, Zhenkun ; Wang, Meng ; Geng, Guozhu ; Liu, Yusi ; Chen, Hong ; Gao, Lei ; Li, Xiaojiao ; Chen, Jing ; Zhang, Hong ; Wu, Min ; Ding, Yanhua ; Liu, Jingrui

BACKGROUNDDue to the rapid development of antimicrobial resistance, the efficacy of most Helicobacter pylori eradication therapies have progressively decreased to an unacceptable level. Rifasutenizol (TNP-2198) is a new molecular entity with a synergistic dual mechanism of action currently under clinical development for the treatment of microaerophilic and anaerobic bacterial infections. We aimed to evaluate the safety, pharmacokinetics, and efficacy of rifasutenizol in healthy Chinese participants and patients with H pylori.METHODSWe conducted four clinical trials of rifasutenizol capsules in healthy participants (aged 18-55 years) and patients with asymptomatic H pylori infection (aged 18-65 years) in a clinical trial centre in Jilin province, China. Trial 1 was a phase 1, double-blind, randomised, placebo-controlled, single ascending dose study, in which participants were enrolled into one of seven rifasutenizol dose groups (50 mg, 100 mg, 200 mg, 400 mg, 600 mg, 800 mg, or 1000 mg) and were randomly assigned in a 4:1 ratio to study drug or placebo. Trial 2 was a phase 1, double-blind, randomised, placebo-controlled, multiple ascending dose study, in which patients were enrolled into one of three rifasutenizol dose groups (200 mg, 400 mg, or 600 mg) and were randomly assigned in a 3:1 ratio to study drug or placebo. Trial 3 was a phase 2a, open-label, randomised, multiple-dose, dose-finding study in which patients enrolled into one of four cohorts were randomly assigned in a 1:1:1:1 ratio to a rifasutenizol dual or triple regimen. Trial 4 was a phase 2b, open-label, randomised, multiple-dose, regimen exploration study, in which patients enrolled into one of five cohorts were randomly assigned in a 2:2:1:1:2 ratio to a rifasutenizol dual therapy, triple therapy, or a control cohort. Block randomisation (block size 4 or 8) was used in all four trials. The key primary endpoints for trials 1, 2, and 3 were the tolerability, safety, and pharmacokinetics of rifasutenizol. For trial 4, the primary endpoint was the eradication rate of H pylori. These four trials were registered at ClinicalTrials.gov (NCT06081699, NCT06081712, NCT06076681, and NCT06076694) and chinadrugtrials.org.cn (CTR20190734, CTR20192553, CTR20212050, and CTR20220625) and are completed.FINDINGSBetween May 9, 2019, and Sept 14, 2022, 78 healthy participants (trial 1: n=10 per cohort in a 4:1 rifasutenizol:placebo ratio; and an additional eight for the food-effect cohort) and 168 patients with asymptomatic H pylori infection (trial 2: n=16 per cohort in a 3:1 rifasutenizol:placebo ratio; trial 3: n=10 per cohort; trial 4: n=10 or n=20 per cohort) were enrolled in the four clinical trials. Single doses of rifasutenizol (50-1000 mg) and multiple doses of rifasutenizol (200 mg to 600 mg, twice a day), either as monotherapy or co-administered with rabeprazole and amoxicillin, showed favourable safety and tolerability profiles. Most adverse events were mild, and no serious adverse events were reported. Rifasutenizol demonstrated a linear pharmacokinetic profile over the dose range of 50-800 mg, and there were no apparent pharmacokinetic interactions between rifasutenizol and the co-administrated drugs. Food intake slightly elevated the area under the plasma concentration-time curve (AUC) of rifasutenizol, and the geometric mean of AUC from time 0 to the last timepoint with a quantifiable concentration (AUC_0-t) and AUC from time 0 to infinity (AUC_0-∞) in the fed state were 1·334 and 1·396 times of those in the fasted state, respectively. There was mild accumulation after continuous administration of rifasutenizol, and the R_ac(AUC) of rifasutenizol 400 mg in the dual and triple regiments in trial 3 were 1·37 and 1·49, respectively. In trial 3, the eradication rates of H pylori with 200 mg, 400 mg, or 600 mg of rifasutenizol in combination with rabeprazole, twice a day for 14 days, were 0% (95% CI 0-31), 30% (7-65), and 40% (12-74), respectively, identifying rifasutenizol 400 mg as the effective dose. In trial 4, H pylori eradication rates with the triple regimen in cohort A (400 mg rifasutenizol, 20 mg rabeprazole sodium, and 1 g amoxicillin) twice a day for 14 days was 95% (95% CI 74-100), and triple therapy (600 mg rifasutenizol, 20 mg rabeprazole sodium, and 1 g amoxicillin) three times a day for 7 days was 100% (69-100).INTERPRETATIONRifasutenizol monotherapy and combination therapy was generally safe and well tolerated in healthy participants and patients with H pylori infection. A triple regimen of 400 mg rifasutenizol capsules, 20 mg rabeprazole sodium enteric-coated tablets, and 1 g amoxicillin capsules twice a day for 14 days showed promising efficacy as a new treatment regimen for H pylori infection.FUNDINGTenNor Therapeutics and National Natural Science Foundation of China.TRANSLATIONFor the Chinese translation of the abstract see Supplementary Materials section.

2022-05-01·Current Medicinal Chemistry2区 · 医学

A Comparative Insight on the Newly Emerging Rifamycins: Rifametane, Rifalazil, TNP-2092 and TNP-2198

2区 · 医学

Review

作者: He, David L ; Wang, Zhi-Peng ; Nazli, Adila ; He, Yun ; Xu, Huacheng

Abstract:Rifamycins are considered a milestone for tuberculosis (TB) treatment because of their proficient sterilizing ability. Currently, available TB treatments are complicated and need a long duration, which ultimately leads to failure of patient compliance. Some new rifamycin derivatives, i.e., rifametane, TNP-2092 (rifamycin-quinolizinonehybrid), and TNP-2198 (rifamycin-nitromidazole hybrid) are under clinical trials, which are attempting to overcome the problems associated with TB treatment. The undertaken review is intended to compare the pharmacokinetics, pharmacodynamics and safety profiles of these rifamycins, including rifalazil, another derivative terminated in phase II trials, and already approved rifamycins. The emerging resistance of microbes is an imperative consideration associated with antibiotics. Resistance development potential of microbial strains against rifamycins and an overview of chemistry, as well as structure-activity relationship (SAR) of rifamycins, are briefly described. Moreover, issues associated with rifamycins are discussed as well. We expect that newly emerging rifamycins shall appear as potential tools for TB treatment in the near future.

2022-03-24·Journal of Medicinal Chemistry1区 · 医学

Design, Synthesis, and Characterization of TNP-2198, a Dual-Targeted Rifamycin-Nitroimidazole Conjugate with Potent Activity against Microaerophilic and Anaerobic Bacterial Pathogens

1区 · 医学

Article

作者: Weiss, William J. ; Lin, Wei ; Ebright, Richard H. ; Ding, Charles ; Robertson, Gregory T. ; Doyle, Timothy ; Ma, Zhenkun ; He, Shijie ; Duncan, Leonard ; Wang, Huan ; Xu, Xiangyi ; Liu, Yu ; Chen, Jing ; Yuan, Ying ; Pulse, Mark ; Molodtsov, Vadim ; Lynch, Anthony Simon ; Zhuang, Zhijun ; Nguyen, Phung

TNP-2198, a stable conjugate of a rifamycin pharmacophore and a nitroimidazole pharmacophore, has been designed, synthesized, and evaluated as a novel dual-targeted antibacterial agent for the treatment of microaerophilic and anaerobic bacterial infections. TNP-2198 exhibits greater activity than a 1:1 molar mixture of the parent drugs and exhibits activity against strains resistant to both rifamycins and nitroimidazoles. A crystal structure of TNP-2198 bound to a Mycobacterium tuberculosis RNA polymerase transcription initiation complex reveals that the rifamycin portion of TNP-2198 binds to the rifamycin binding site on RNAP and the nitroimidazole portion of TNP-2198 interacts directly with the DNA template-strand in the RNAP active-center cleft, forming a hydrogen bond with a base of the DNA template strand. TNP-2198 is currently in Phase 2 clinical development for the treatment of Helicobacter pylori infection, Clostridioides difficile infection, and bacterial vaginosis.

项与瑞法舒坦唑相关的新闻（医药）

2024-11-19

·生物谷

晚讯｜全球首个角膜病iPS细胞疗法成功恢复患者视力、2023年度中国医药企业研发指数”在沪发布！

1. 全球首个角膜病iPS细胞疗法成功恢复患者视力全球首次利用人类诱导多能干细胞培养出角膜组织，并成功移植使角膜缘干细胞缺乏症患者视力恢复，疗效显著且无明显副作用。 2. 研发创新彰显中国力量：“2023年度中国医药企业研发指数”在沪发布 “2023年度中国医药企业研发指数”发布，显示中国医药企业在研发创新领域取得显著成就，该指数由中国国际经济交流中心等五家单位共同发布，全面剖析了中国医药企业的研发实力，历经三届已成为行业名片。此次发布的指数吸纳了多元智慧，建立了科学的综合评估体系，细分为不同行业。过去十一年，中国医药研发指数稳步增长，研发投入的增加是主要动力。 3. 斩获广东首个！BEIZRAY获美国FDA批准上市,贝海生物全球化战略再进一步近期，珠海贝海生物技术有限公司（以下简称“贝海生物”）宣布，其自主研发的新药BH009（商品名:BEIZRAY®）正式获得美国食品药品监督管理局（FDA）上市批准，主要用于乳腺癌、非小细胞肺癌、头颈部鳞癌、前列腺癌以及胃癌的治疗。BH009是广东省首个直接向美国FDA递交新药申请（NDA）并在美国获批的新药，贝海生物拥有其在全球范围内的完全自主知识产权。 BH009是由贝海生物自主研发的多西他赛改良型新药，也是多西他赛上市近三十年来首个通过临床验证并具有明显临床优势的改良型新药。值得关注的是，从2019年立项开始，仅耗时5年BH009便成功获得美国FDA上市批准，展现了贝海生物作为创新药企的卓越研发能力和高效执行力。而这，不仅是贝海生物在抗肿瘤药物研发领域的厚积薄发和全球化战略蓝图上浓墨重彩的续写，也彰显了中国生物医药企业在全球舞台上的崛起之势。 4. 中国、美国、日本治疗癌症的好医院有哪些？2024~2025肿瘤医院TOP10出炉《美国新闻与世界报道》发布了2024-2025美国最佳医院排名，中国也发布了医院排行榜。全球肿瘤医生网列出了美国、日本、中国治疗癌症的医院排名，供患者参考。 5. 上周，国内3家创新药公司宣布完成超亿元融资上周，通瑞生物获超1亿美元A+轮融资，英派药业获2.5亿元人民币D++轮融资，均用于创新药研发与商业化。莱芒生物也完成超亿元融资。 6. 30年首个，幽门螺杆菌“首创新药”更新进展丹诺医药的全球首创新药TNP-2198成功完成III期临床试验，显示其在治疗幽门螺杆菌感染方面相比铋剂四联有多方面优势，根除率超过90%，且未分离到耐药菌株。本文仅用于学术分享，转载请注明出处。若有侵权，请联系微信：bioonSir 删除或修改！

上市批准临床3期细胞疗法申请上市医药出海

2024-11-19

·BioBAY

国内首款！迈杰医学伴随诊断PD-L1抗体试剂获批上市

近日，BioBAY园内苏州工业园区科技领军人才企业——迈杰医学研发的PD-L1（JS311）抗体试剂（免疫组织化学法）（商品名：迈泽康）通过国家优先审批通道获批上市。 PD-L1（JS311）抗体试剂（免疫组织化学法）这是国内首款用于三阴性乳腺癌适应症的PD-L1药物伴随诊断试剂，也是园区今年首个获批的国家优先医疗器械产品。该产品的获批填补了国内空白，满足了临床急需，将重新定义三阴性乳腺癌一线治疗的新标准，为患者提供新的治疗选择。迈杰医学迈杰转化医学研究（苏州）有限公司成立于2013年，专注于通过转化医学为癌症精准医疗提供整体解决方案。作为伴随诊断整体解决方案领导者，迈杰医学拥有综合转化医学技术支持药物临床转化、伴随诊断产品（CDx）开发和用药指导检测三大业务，已与全球400+创新药企及技术公司展开合作，并开发验证了数百个生物标记物及方法学，支持上百个药物临床试验。截至目前，迈杰医学共有20+款产品获得药监批准，涵盖实体肿瘤和血液肿瘤，其中包括国内首个获批的JAK2-V617F突变检测试剂盒及用于免疫治疗的PDL-1检测试剂盒，以及8款CE认证产品。 ▌文章来源：SIP科技创新责编：何文正审核：任旭推荐阅读上市企业丨亚盛医药：首个国产原研Bcl-2抑制剂！APG-2575新药上市申请获受理并被推荐纳入优先审评研发动态丨丹诺医药：幽门螺杆菌首创新药TNP-2198 III期临床试验达到主要终点研发动态丨首款AI驱动药物迎来里程碑进展，英矽智能发布ISM001-055临床2a期实验积极顶线数据

上市批准优先审批诊断试剂临床3期免疫疗法

2024-11-18

·氨基观察

我国创新药市场规模已突破1000亿元；减重版司美格鲁肽在上海开出全国首批处方

氨基观察-创新药组原创出品作者 | 黄凯我国创新药市场进步迅速。 11月17日，工业和信息化部统计数据显示：今年以来，我国有37个创新药、51个创新医疗器械获批上市，截至目前，我国创新药市场规模突破1000亿元。减重版司美格鲁肽登陆国内市场。 11月17日，诺和诺德宣布，减重版司美格鲁肽诺和盈正式在国内商业化上市，该药能够实现平均17%的体重降幅。11月18日，诺和盈在上海复旦大学附属中山医院开出全国首批处方。康诺亚再次通过NewCo形式出海。 11月17日，康诺亚宣布，其子公司已订立独家许可协议，授予PML在全球（不包括中国内地、香港、澳门及台湾）研究、开发、生产、注册及商业化BCMAxCD3双特异性抗体CM336的独家权利。根据协议：康诺亚集团将收取1600万美元的首付款和近期付款，同时获得Ouro Medicines的少数股权作为交易对价的一部分。在过去的一天里，国内外医药市场还有哪些热点值得关注？让氨基君带你一探究竟。 / 01 / 市场速递 1）减重版司美格鲁肽在上海开出全国首批处方 11月18日，全球首个用于长期体重管理的胰高糖素样肽-1受体激动剂（GLP-1）周制剂诺和盈，在上海复旦大学附属中山医院开出全国首批处方。11月17日，诺和诺德宣布，减重版司美格鲁肽正式在国内商业化上市，该药能够实现平均17%的体重降幅。 2）袁纪军加盟复宏汉霖，负责创新中心整体战略规划日前，复宏汉霖官网显示，其团队成员发生了变化：袁纪军作为首席科学官加盟复宏汉霖，全面负责后者创新中心的整体战略规划、团队管理和日常运营工作。 3）康诺亚BCMAxCD3双抗以NewCo形式出海 11月17日，康诺亚宣布，其子公司已订立独家许可协议，授予PML在全球（不包括中国内地、香港、澳门及台湾）研究、开发、生产、注册及商业化BCMAxCD3双特异性抗体CM336的独家权利。根据协议：康诺亚集团将收取1600万美元的首付款和近期付款，同时获得Ouro Medicines的少数股权作为交易对价的一部分。 4）我国创新药市场规模已突破1000亿元 11月17日，工业和信息化部统计数据显示：今年以来，我国有37个创新药、51个创新医疗器械获批上市，截至目前，我国创新药市场规模突破1000亿元。 / 02 / 资本信息 1）九源基因港交所过聆讯日前，港交所官网显示，创新药企杭州九源基因通过聆讯，即将上市 2）扬奇医芯完成数千万元Pre-A轮融资日前，深圳扬奇医芯宣布完成数千万元Pre-A轮融资，本轮融资将主要用于获批产品市场推广、新产品研发报批与宠物放疗市场拓展。 / 03 / 医药动态 1）康缘药业KYS202003A注射液获临床许可 11月18日，据CDE官网，康缘药业KYS202003A注射液获临床许可，拟开展治疗晚期实体瘤患者的研究。 2）万泰生物9价HPV疫苗男性适应症获临床许可 11月18日，据CDE官网，万泰生物9价HPV疫苗获临床许可，将开展针对男性人群适应症的临床试验。 3）派金生物PJ016注射液获临床许可 11月18日，据CDE官网，派金生物PJ016注射液获临床许可，拟开展治疗晚期实体瘤患者的研究。 4）华东医药HDM1005注射液获美国FDA临床试验批准 11月18日，华东医药公告，多肽类人GLP-1受体和GIP受体的双靶点长效激动剂HDM1005注射液药品临床试验申请已FDA，可在美国开展I期临床试验。 5）丹诺医药TNP-2198临床III期试验达到主要终点 11月18日，丹诺医药官网宣布，用于治疗幽门螺杆菌感染新药TNP-2198成功完成III期临床试验并达到研究预设的主要终点指标，同铋剂四联相比体现多方面优势。 6）海森生物HST101 III期临床试验完成首例受试者入组给药 11月16日，海森生物宣布，第三代PCSK9抑制剂以下简称HST101完成III期临床试验首例受试者入组给药， 7）华辉安健立贝韦塔单抗获美国FDA突破性疗法认定 11月18日，华辉安健宣布，立贝韦塔（HH-003）单抗近日获美国FDA授予突破性疗法认定，用于治疗慢性丁型肝炎病毒感染。 / 04 / 器械跟踪 1）海杰亚复合式冷热消融设备获注册许可 11月18日，据NMPA官网，海杰亚复合式冷热消融设备获注册许可。 2）乐普医疗无创血糖仪获注册许可 11月18日，据NMPA官网，乐普医疗无创血糖仪获注册许可。 3）心玮医疗颅内动脉瘤栓塞辅助支架获注册许可 11月18日，据NMPA官网，心玮医疗颅内动脉瘤栓塞辅助支架获注册许可。 4）恒瑞迦俐生外周球囊扩张导管获注册许可 11月18日，据NMPA官网，恒瑞迦俐生外周球囊扩张导管获注册许可。 5）长木谷医疗髋关节置换手术导航系统获注册许可 11月18日，据NMPA官网，长木谷医疗髋关节置换手术导航系统获注册许可。 / 05 / 海外药闻 1）每月一次的MASH疗法积极临床结果公布日前，Boston Pharmaceuticals宣布，2期试验显示，每月一次的长效人类成纤维细胞生长因子21（FGF21）类似物efimosfermin alfa，可显著改善肝纤维化≥1级，且MASH不会恶化，并且在24周内MASH缓解且肝纤维化不会恶化。 2）卫材/渤健阿尔茨海默病疗法有望获欧盟批准日前，卫材和渤健宣布，欧洲药品管理局人用药品委员会建议批准，其阿尔茨海默病疗法Leqembi，用于治疗经临床诊断为阿尔茨海默病导致的轻度认知障碍和轻度痴呆的成人患者。 PS：欢迎扫描下方二维码，添加氨基君微信号交流。

引进/卖出CSCO会议并购上市批准

100 项与瑞法舒坦唑相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
厌氧菌感染	临床3期	中国	丹诺医药（苏州）有限公司	2023-05-06
细菌性阴道炎	临床3期	中国	丹诺医药（苏州）有限公司	2023-05-06
艰难梭菌腹泻	临床3期	中国	丹诺医药（苏州）有限公司	2023-05-06
消化道感染	临床3期	中国	丹诺医药（苏州）有限公司	2023-05-06
幽门螺杆菌感染	临床3期	中国	丹诺医药（苏州）有限公司	2023-05-06
梭菌感染	临床2期	中国	丹诺医药（苏州）有限公司	2021-09-16
腹泻	临床2期	中国	丹诺医药（苏州）有限公司	2021-09-16
艰难梭菌感染	临床前	中国	丹诺医药（苏州）有限公司	2022-02-17
艰难梭菌感染	临床前	美国	Jones Microbiology Institute, Inc.	2022-02-17

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT05857163 (NEWS) 人工标引	临床3期	幽门螺杆菌感染	700	TNP-2198三联方案	(憲蓋壓鏇鬱觸襯築構顧) = 糧膚簾獵鹽襯鏇願製夢繭艱簾繭構顧襯壓鹹簾 (壓鑰選獵蓋製築糧膚築 ) 达到更多	积极	2024-11-18
				铋剂四联方案	(憲蓋壓鏇鬱觸襯築構顧) = 衊衊獵築襯夢觸艱築壓繭艱簾繭構顧襯壓鹹簾 (壓鑰選獵蓋製築糧膚築 ) 达到更多
NCT06076681 \| NCT06076694 \| NCT06081699 \| NCT06081712 (Pubmed)	临床1/2期	幽门螺杆菌感染	-	Rifasutenizol 400 mg	醖膚顧鏇鹽鹹鏇積艱鹽(夢範鹹鬱壓築獵網鏇範) = 獵鬱衊鏇齋鏇觸醖構醖夢憲艱鬱窪鑰遞觸艱憲 (壓膚憲遞範積淵觸遞製, 7 ~ 65)	-	2024-02-01
				Rifasutenizol 600 mg	醖膚顧鏇鹽鹹鏇積艱鹽(夢範鹹鬱壓築獵網鏇範) = 顧膚鹽夢餘壓觸窪衊鑰夢憲艱鬱窪鑰遞觸艱憲 (壓膚憲遞範積淵觸遞製, 12 ~ 74)
NCT06076694 (CTgov)	临床2期	幽门螺杆菌感染	80	TNP-2198+Amoxicillin+Rabeprazole Sodium (Group A)	淵網繭廠簾顧窪餘壓衊(糧願齋鬱鹽願憲積積獵) = 選觸簾艱鬱製繭遞網選獵餘齋膚膚醖壓構鹹遞 (壓顧淵觸窪築觸餘憲憲, 簾壓積襯餘淵鹽簾蓋網 ~ 鹽鑰衊鹹範壓艱壓醖築) 更多	-	2023-12-12
				TNP-2198+Amoxicillin+Rabeprazole Sodium (Group B)	淵網繭廠簾顧窪餘壓衊(糧願齋鬱鹽願憲積積獵) = 遞壓築積觸積鹹糧製餘獵餘齋膚膚醖壓構鹹遞 (壓顧淵觸窪築觸餘憲憲, 製繭製願獵鹽鬱網觸膚 ~ 觸網糧艱選製餘構糧醖) 更多
NCT06076681 (CTgov)	临床1/2期	幽门螺杆菌感染	40	TNP-2198+Rabeprazole Sodium (Group A)	觸餘糧獵選簾襯繭醖餘(膚繭選簾構範襯觸淵襯) = 獵襯網築顧窪鹹獵夢鬱選壓艱願醖膚製鬱觸鹽 (顧繭鏇製廠觸壓鬱選鬱, 鬱遞夢衊壓壓醖壓網膚 ~ 壓膚繭網鏇窪選構淵鑰) 更多	-	2023-11-22
				TNP-2198+Rabeprazole Sodium (Group B)	觸餘糧獵選簾襯繭醖餘(膚繭選簾構範襯觸淵襯) = 鹽範顧艱願選鏇衊鬱獵選壓艱願醖膚製鬱觸鹽 (顧繭鏇製廠觸壓鬱選鬱, 簾遞淵膚餘鬱願襯繭糧 ~ 繭範製齋製鏇顧醖製齋) 更多